Please try another search
PD-Rx Pharmaceuticals, Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was USD 21.27 million compared to USD 28.72 million a year ago. Net loss was USD 0.098064 million compared to net income of USD 3.03 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to basic earnings per share from continuing operations of USD 1.83 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to diluted earnings per share from continuing operations of USD 1.83 a year ago.
Period Ending: | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 |
---|---|---|---|
Total Revenue | 21.27 | 28.72 | 21.6 |
Gross Profit | 6.71 | 11.06 | 6.96 |
Operating Income | -0.19 | 4 | 0.876 |
Net Income | -0.098 | 3.03 | 1.86 |
Period Ending: | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 |
---|---|---|---|
Total Assets | 12.95 | 13.22 | 10.9 |
Total Liabilities | 1.7 | 1.87 | 2.42 |
Total Equity | 11.25 | 11.35 | 8.48 |
Period Ending: | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 |
---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 1.79 | 3.24 | -0.466 |
Cash From Investing Activities | -0.427 | -0.503 | -0.086 |
Cash From Financing Activities | -0.001 | -0.165 | |
Net Change in Cash | 1.36 | 2.57 | -0.552 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review